leadf
logo-loader
viewShield Therapeutics PLC

Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive of ongoing discussions

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis complete, the long term clinical durability of Feraccru (to be called Accrufer in US), its cost-efficacy and ease-of-use when compared to the standard IV iron, support discussions with potential US partners.

Quick facts: Shield Therapeutics PLC

Price: 136.5 GBX

LSE:STX
Market: LSE
Market Cap: £159.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics: 'US talks ongoing with progress being made'

Proactive Research analyst Emma Ulker says US partnering discussions at Shield Therapeutics (LON:STX) are progressing and it's a key factor given that the US represents around 70% of the US$3bn global iron replacement market. Ulker adds that the balance sheet was recently bolstered by an...

on 05/06/2020

2 min read